The initiation of coverage by Goldman Sachs, a major investment bank, with a Buy rating indicates a positive outlook for Syndax Pharmaceuticals. The price target of $30 suggests that the analyst sees significant upside potential for the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.